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The discovery of CXCR4 and CCR5 in 1996 by several
A u t h o r sa st h et w om a i nm a n d a t o r yr e c e p t o r sf o r
HIV-1 entry into CD4+ cells will be recognized as a
milestone of AIDS research. The present issue on “Dif-
ferential use of CCR5 versus CXCR4 by HIV-1. Patho-
genic, Translational and Clinical Open Questions” is
intended to summarize the most update aspects on the
biology of such HIV-1 coreceptors, including contribu-
tions by some of the most renown scientists in the field.
In less than 10 years, a new anti-HIV drug (Mara-
viroc) blocking CCR5 has been licensed for use in the
treatment of infected individuals and new candidate vac-
cines and microbicides are under study, targeting the
interface between gp120 Env and chemokines receptors.
Deeper and broader appreciation of coreceptors in AIDS
immunopathogenesis has been made possible, i.e. evalu-
ating the occurrence and relevance of “natural” anti-
CCR5 antibodies.
In these years, CCR5 has clearly emerged as the key
co-receptor and the AIDS pandemic is essentially driven
by viral strains exclusively exploiting this entry co-
receptor named “R5-virus” ("R5-related” disease). On
the contrary, CXCR4-using viruses are confined to the
advanced immunodeficient stage of subtype B infection,
accelerating disease progression. Qualitative and quanti-
tative differences between CCR5 and CXCR4-using
viruses (usually dualtropic R5X4) have been identified
and a multiple “gatekeeper” hypothesis has been pro-
posed. In particular, experimental data have been col-
lected showing that binding and infection through
CCR5 results in superior and differential signaling capa-
city, as well as viral replication and mother-to-child
transmission.
Finally, discovery of the chemokine entry co-receptors
has also pointed out one of the main limits of non-
human primate models of HIV infection based on SIV
strains, which exclusively use CXCR4 as coreceptor.
In summary, the present issue updates some of the
most relevant lines of research revolving around the
interaction between HIV and its host target cells, in
which CCR5 and CXCR4 chemokine receptors play a
key role and represent a focal point for HIV/AIDS
pathogenetic studies as well as therapeutic and preven-
tive intervention strategies.
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